Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTN6Y9A)

• DTT Name: CD40L receptor (CD40) DTT Info
• Gene Name: CD40

Molecule-Related Drug & Molecule List

17 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[1]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[2]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[3]
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[4]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[4]
Dazodalibep	DM7YII9	Kidney transplant rejection	NE84	Phase 2	[5]
Frexalimab	DMMJTYP	Multiple sclerosis	8A40	Phase 2	[6]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[7]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[8]
ABBV-323	DM49O6Y	Crohn disease	DD70	Phase 1	[4]
CDX-1140	DMUGN0J	Melanoma	2C30	Phase 1	[9]
CP-870,893	DM32TFO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
NG-350A	DMQK5ET	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
RG6189	DMYFGN4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[14]
YH003	DM84TF8	Aggressive cancer	2A00-2F9Z	Phase 1	[15]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HuCD40L	DMTGCA6	Solid tumour/cancer	2A00-2F9Z	Terminated	[16]
RhuCD40L	DMW4UTB	N. A.	N. A.	Terminated	[17]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-CD40-XTEN	DMGZM6V	Rheumatoid arthritis	FA20	Investigative	[2]
CD154	DM9BMDO	Discovery agent	N.A.	Investigative	[18]
Human CD40 agonist ligand	DM8FLVH	Discovery agent	N.A.	Investigative	[2]
PG-120	DMWP0BX	Autoimmune diabetes	5A10	Investigative	[2]
YH008	DMTIP9S	Aggressive cancer	2A00-2F9Z	Investigative	[19]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [3] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [6] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [7] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [8] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [9] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019 Feb;68(2):233-245.
• [10] Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.
• [11] Clinical pipeline report, company report or official report of Genmab.
• [12] Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
• [13] Clinical pipeline report, company report or official report of Roche
• [14] Clinical pipeline report, company report or official report of Shattuck Labs.
• [15] Clinical pipeline report, company report or official report of Biocytogen
• [16] Recombinant human CD40 ligand inhibits simian immunodeficiency virus replication: a role for interleukin- 16. J Med Primatol. 1999 Aug-Oct;28(4-5):190-4.
• [17] Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 2001 Oct 15;61(20):7556-62.
• [18] Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001 Mar;7(3):691-703.
• [19] Clinical pipeline report, company report or official report of Biocytogen